Alterity Therapeutics Ltd ADR ATHE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATHE is a good fit for your portfolio.
News
-
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
-
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
-
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
-
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
-
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
-
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
Trading Information
- Previous Close Price
- $2.33
- Day Range
- $2.26–2.47
- 52-Week Range
- $1.55–5.41
- Bid/Ask
- $2.21 / $2.35
- Market Cap
- $19.73 Mil
- Volume/Avg
- 31 / 86,747
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
Valuation
|
Metric
|
ATHE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATHE
|
|---|---|
Quick Ratio | 5.58 |
Current Ratio | 6.17 |
Interest Coverage | — |
Quick Ratio
ATHE
Profitability
|
Metric
|
ATHE
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATHE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bsfztyhzm | Yzgw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bhbdvynml | Qlbmfp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mhdnmdrwh | Cnncxj | $97.8 Bil | |
MRNA
| Moderna Inc | Plmpsmwt | Rcnx | $38.8 Bil | |
ARGX
| argenx SE ADR | Lsvhjwfcw | Vhxyh | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Lnktqbrmv | Bbb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nnbvbpvgw | Psmmql | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hqplxjknh | Pzqdgvk | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lkrqlphnlw | Wgrlkz | $12.5 Bil | |
INCY
| Incyte Corp | Fmtgndvf | Jlfbkrh | $11.5 Bil |